Evidence map›Paper›PMID 32360588›Full record

ArticleBone2020

Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance.

Jad G Sfeir, Tito D Pena Guzman, Lucia Bedatsova, Stephen M Broski, Matthew T Drake

Open access · greenAbstract read
In one paragraph

Article in Bone, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jad G SfeirDivision of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, - Rochester, MN, United States of America; Division of Geriatric Medicine and Gerontology, Mayo Clinic, - Rochester, MN, United States of America; Robert and Arlene Kogod Center on Aging, Mayo Clinic, - Rochester, MN, United States of America.
Tito D Pena GuzmanDivision of General Internal Medicine, Mayo Clinic, - Rochester, MN, United States of America.
Lucia BedatsovaDivision of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, - Rochester, MN, United States of America.
Stephen M BroskiDivision of Musculoskeletal Radiology, Mayo Clinic, - Rochester, MN, United States of America.
Matthew T DrakeDivision of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, - Rochester, MN, United States of America; Robert and Arlene Kogod Center on Aging, Mayo Clinic, - Rochester, MN, United States of America; Division of Hematology, Mayo Clinic, - Rochester, MN, United States of America. Electronic address: Drake.Matthew@mayo.edu.
Mayo Clinic in Florida · USMayo Clinic · US

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
NCATS NIH HHS UL1 TR002377
6 · The paper itself

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a common finding in clinical practice. The risk for developing MGUS increases with aging in parallel with age-associated increases in fracture risk. Although there is good evidence that patients with MGUS suffer from increased fracture risk, no standardized guidelines exist for the evaluation and/or management of skeletal health in patients with MGUS. Trabecular bone score (TBS), a texture index derived from lumbar spine (LS) dual-energy x-ray absorptiometry (DXA) images, provides information about trabecular microarchitecture independent of bone mineral density (BMD). We retrospectively identified 155 adult patients diagnosed with MGUS between 2005 and 2018. This group was matched 1:1 to a control group for sex, age and BMI. TBS was performed retrospectively, and values categorized as low (≤1.23), intermediate (1.23-1.31) or normal (>1.31). Patients had a mean ± SD age of 69.6 ± 10.0. BMD was performed within a median of 28 months (IQR 1-78) of MGUS diagnosis. Cases had a non-statistically significant higher rate of fractures compared to control subjects (27 vs. 17, respectively, p = 0.1). Patients with MGUS had a significantly lower TBS (1.31 ± 0.13 vs. 1.34 ± 0.12, respectively, p < 0.05) and lower LS BMD (1.215 ± 0.223 vs. 1.275 ± 0.247, p < 0.05) compared to controls. Although fractures occurred more commonly in those control subjects with significantly lower TBS values, this was not the case in subjects with MGUS (TBS 1.299 vs. 1.313 in cases with vs. without fractures p = 0.313). Similarly, there was no difference in T-scores in cases with or without fractures (-1.33 vs. -1.37, respectively, p = 0.56). Despite patients with MGUS having a significantly increased fracture risk compared to age-, sex- and BMI-matched control subjects, neither assessment of BMD nor TBS, obtained within two years of MGUS diagnosis, were able to accurately risk stratify MGUS patients. Unlike control subjects, patients with MGUS tend to fracture despite normal BMD and intermediate or normal TBS values, suggesting that deterioration of cortical rather than trabecular skeletal components may be more important for the increased fracture risk seen in MGUS.

Indexed as

Monoclonal Gammopathy of Undetermined SignificanceOsteoporotic FracturesAbsorptiometry, PhotonAdultBone DensityCancellous BoneChild, PreschoolHumansLumbar VertebraeRetrospective StudiesRisk AssessmentBone mineral densityFractureMonoclonal gammopathyMyelomaTrabecular bone score

Identifiers

PMID32360588
PMCPMC7354210
OpenAlexW3020922347

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.